Community Practice Connections™: Visualizing New Treatment Pathways for Anemia in Chronic Kidney Disease
Released On
January 30, 2023
Expires On
January 30, 2024
Media Type
Internet
Completion Time
60 minutes
Specialty
Hematology, Nephrology, Cardiology, Primary Care
Topic(s)
Blood Disorders, Diabetes, New Drugs
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by an educational grant from GlaxoSmithKline.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credits™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity is directed toward hematologists, nurses, and other health care professionals involved in the treatment of patients with CKD-related anemia.
Program Overview
Anemia is a common complication in chronic kidney disease (CKD) and is associated with a reduced quality of life, an increase in morbidity and mortality and higher costs. Anemia is associated with major complications for patients with CKD, including impaired cognition, sleep disturbance, and increased cardiac risk. Yearly treatment costs are estimated to more than three-fold higher in patients with anemia than in those without. Racial and ethnic minorities suffer disproportionately from progressive pre-end-stage renal disease (pre-ESRD), with more than 3 times the incidence of ESRD compared to Whites. Despite guideline recommendations, hemoglobin and iron stores are measured less frequently than recommended. A high proportion of patients in the US were identified as having no measurement of iron parameters, indicating that this is an area for quality improvement in care of patients with CKD.
This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the American Society of Hematology annual meeting, held in December 2022. This unique and engaging multi-media activity is ideal for the community-based clinician and focuses on the practical aspects managing patients with CKD and anemia, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.
Learning Objectives
- Upon completion of this activity, participants should be better able to:
-
- Discuss the burden of anemia in patients with CKD
- Review the pathophysiology of anemia in these patients
- Implement guideline-based recommendations for the evaluation of CKD-associated anemia
- Formulate individualized management plans for patients with anemia and CKD
Faculty
Steven Fishbane, MD
Professor of Medicine
Zucker School of Medicine at Hofstra/Northwell
Hofstra University
Chief of Nephrology
Northwell Health
Great Neck, NY
Ellie Kelepouris MD, FACP, FAHA
Professor of Clinical Medicine
Perelman School of Medicine
University of Pennsylvania
Director of Outpatient Dialysis Programs
Penn Medicine
Philadelphia, PA
Jay B. Wish, MD
Medical Director
Outpatient Dialysis
Indiana University Hospital
Chief Medical Officer, Dialysis
IU Health
Professor of Clinical Medicine
Indiana University School of Medicine
Indianapolis, IN
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.
- Steven Fishbane, MD
-
- Grant/Research Support: AstraZeneca, GSK
- Consultant: AstraZeneca, GSK
- Ellie Kelepouris MD, FACP, FAHA
-
- Grant/Research Support: CAR-HF Vifor Pharma
- Consultant: AstraZeneca, Bayer, Boehringer Ingelheim-Lilly, Vifor Pharma
- Jay B. Wish, MD
-
- Consultant: Akebia Therapeutics, Amgen, AstraZeneca, CSL Behring, Disc Medicine, FibroGen, GSK, Otsuka, Rockwell Medical, Vifor Pharma
- Speakers’ Bureau: Akebia Therapeutics, AstraZeneca
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Instructions for Participation and Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.